Connect with us

Finance

Greece has doubled its minimum investment for a golden visa

Avatar

Published

on

Whether it is a temporary residence in a far compartment Or permanent change to live in a farm in PortugalWorkers are taking advantage of their newfound ability to not go to the office.

As always, the rich take it step forward. They have increasingly turned into Golden Visa Programs Where investing or buying real estate can give individuals a residence permit and a pathway to citizenship.

Some people aren’t very enthusiastic about the herd of digital nomads or wealthy individuals who choose to live part- or full-time in a different country: the people of those countries. in early SeptemberGreek Prime Minister Kyriakos Mitsotakis doubled the minimum investment price in order to get the gold medal visa In the country, he raised the price from 250,000 euros to 500,000 euros per International Consultant.

Advertisement

Many are looking to get a golden visa due to the inflated cost of daily expenses and housing in the US, as Get Golden Visa found in exploratory study Of the 320 applicants, 29% were motivated by the high cost of living. But there is a ripple effect, and this new influx of wealthy people looking for cheaper properties is likely to drive Greek citizens out of their housing market.

Reportedly, Mitsotakis said in early September, “In order to increase real estate affordability for Greeks, we are now increasing the minimum investment required to issue a golden visa from €250,000 to €500,000 (£434,000, $500,000)” . , to me International Consultant.

Mitsotakis does not stand alone.

Europe is taking drastic measures

From JuneThe minimum investment in Turkey to obtain citizenship by investment program has been increased from 250 thousand dollars to 400 thousand dollars. and in WalkThe European Commission has pushed EU governments to terminate their citizenship by investment programmes, noting specifically this Wealthy Russians Those supporting or participating in the invasion of Ukraine can benefit from the mentioned programmes.

Late Septemberthe European Commission continued to push it, announcing that it would try Malta as a plotter breaking the rules By not requiring investors to live in the country.

Advertisement

The current Portuguese visa scheme or program has also been the subject of much controversy. The left-wing bloc in Portugal rejected the Portuguese Communist Party’s plan to overthrow the local golden visa mayo.

The left-wing bloc commented on Twitter, “Golden visas only serve the oligarchs who want to launder their wealth. They do not serve the population in any part of the country, they only harm them.” The Portuguese Communist Party added that these new residents are not helping to stimulate the local economy, arguing that “there was almost no productive investment or job creation” only “a clear contribution to real estate” disrupting the affordable housing market, Portugal.com reported.

Part of the price increase for Greece comes from the expectation of increased interest in golden visa applicants. “We expect a strong resurgence of interest from abroad in buying and renting property in Greece, particularly with regard to luxury holiday homes in popular tourist destinations and on islands in the Cyclades, in Crete and Corfu,” Kyriakos Ixidis, Managing Partner Berkshire Hathaway HomeServices Athena Real Estate, according to SchegenVisa.

Raising the price from 250,000 euros is not shocking SpainAnother hot ticket for golden visas, it already had a minimum investment in the price. But Greece’s choice to monitor this increased interest in accommodation by investment rather than simply monetization stands apart from Portugal. Recent Visa Policies. In early October, Portugal announced the time out They reveal a digital nomad program for workers who want to stay in the country for up to a year. Portugal is not alone, like countries Thailand And the Bali Visas for remote workers rolled out.

Although this policy requires no investment, it is a sign that some countries are looking to tap into travel-hungry remote labor at all costs, while others are looking to pump the brakes in the new direction.

Advertisement

Sign up for Wealth Features Email list so you don’t miss our biggest features, exclusive interviews and investigations.

Source link

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published.

Finance

ABB agrees to pay $315 million to settle coordinated African bribery investigation (NYSE:ABB)

Avatar

Published

on

J2R/iStock Editorial via Getty Images

ABB (New York Stock Exchange:ABB) She agreed to pay more than $315 million The US Department of Justice announced on Friday that it is ending a multinational investigation into the bribery of a high-ranking official of South Africa’s state-owned energy company Ascom.

ABB (ABB) bribed an Eskom official during 2014-2017 “in order to corruptly obtain classified information and win lucrative contracts,” the DOJ said.

Advertisement

The company’s subsidiaries also pleaded guilty to one count of conspiracy to violate anti-bribery provisions of the US Foreign Corrupt Practices Act.

The Justice Department said its decision was coordinated with prosecutors in South Africa and Switzerland, as well as the US Securities and Exchange Commission.

The company said in September it had set aside $325 million to cover costs related to the investigations surrounding the Kozel power plant in South Africa.

ABB’s (ABBQ3 results included above-average revenue and order growth, as well as the best margins seen in many years, but the next 12-18 months should be more challenging for reported revenue and order growth, Stephen Simpson writes in Post analysis on the search for alpha.

Source link

Advertisement

Continue Reading

Finance

The Swedish scientist behind the Alzheimer’s drug has big ambitions

Avatar

Published

on

As the Japanese pharmaceutical company Eisai presented data this week confirming that it had developed the first drug to slow cognitive decline in Alzheimer’s patients, the audience applauded at a conference in San Francisco.

Among those present was Lars Lanfelt, a little-known Swedish scientist invented The pioneering drug, known as lecanemab, would make a fortune if approved and successfully marketed.

BioArctic, the company he co-founded in 2003 with Pär Gellerfors, struck a licensing deal on monoclonal antibody therapy with Eisai in 2007, giving it hundreds of millions of dollars in milestone payments and royalties on lecanemab sales.

About 55 million people suffer from dementia worldwide and Alzheimer’s disease accounts for up to 70 percent of these cases, according to the World Health Organization.

Analysts predict that the drug could generate sales of up to $10 billion a year, a prospect that would turn BioArctic, as well as Eisai and its co-owner of the drug, US biotech Biogen.

Advertisement

“It’s nice to have money but that’s not what motivates me. It was the science and the opportunity to build a Swedish company,” the 73-year-old told the Financial Times.

“We want [BioArctic] To be a complete pharmaceutical company: this is our ambition.

Brain scan for Alzheimer’s disease © BSIP SA / Alamy

Shares in BioArctic, which has just 75 employees, have more than tripled in value since Eisai revealed in September that lecanemab slowed the rate of cognitive decline in early-stage Alzheimer’s patients by 27 percent.

The Stockholm-listed company is now worth nearly $2 billion and hiring quickly, with ambitions to sell the drug in the Nordic countries where it owns the rights to lecanemab in collaboration with Eisai.

Lecanemab could be approved in the US as early as January under the US Food and Drug Administration’s accelerated approval pathway. But significant hurdles remain, including satisfying doctors’ concerns about its safety and whether the clinical benefits justify the risks from side effects.

Advertisement

Investors also need to be convinced that Eisai will not repeat the mistakes of its partner Biogen, whose shares plunged last year after the failed launch of a similar Alzheimer’s drug called aducanemab that the Japanese group also helped develop.

Biogen initially priced the one-year Aducanemab treatment at $56,000 despite concerns among some health experts who cautioned there was no conclusive evidence of its benefits.

Analysts said this week’s presentation of comprehensive data on licanimab at the Alzheimer’s Clinical Trials Conference in San Francisco, along with the publication of a peer-reviewed article in the New England Journal of Medicine, was a positive development.

“Is it a cure? No. Are we there yet? No, but the data set is clean and shows clear benefit,” said Evan Segerman, an analyst at BMO Capital Markets.

“Based on this data, we are very confident in lecanemab’s approval and eventual reimbursement for the Centers for Medicare and Medicaid Services (CMS),” he said.

Advertisement
BioArctic’s lab and offices in Stockholm, Sweden, where early research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s is carried out © BioArctic / Gustav Gräll

The decision by CMS, the US federal agency that administers national insurance plans, to limit insurance coverage for aducanemab to people undergoing clinical trials hurt the drug’s commercial prospects.

Despite the euphoria in San Francisco this week, some researchers and investors remain cautious about the prospects for lecanemab, a drug that targets sticky plaques called beta-amyloid that build up in the brain. They say the treatment produces only “moderate” clinical benefits compared to a placebo and can cause serious side effects including brain bleeding.

The Death cases Two of the patients treated on likanimab, who were also taking blood-thinning medications, also raised questions about whether large numbers of patients on anticoagulants could eventually be excluded from taking the treatment.

“I suspect that the lack of clear clinical efficacy will mean that licanimab will not be widely taken up in healthcare systems around the world,” said Robert Howard, professor of geriatric psychiatry at University College London.

Lanvelt disputes that assessment, arguing that a 27 percent reduction in the rate of cognitive decline is clinically significant and sufficient for the drug to be approved and released. He said the results of the experiment also confirmed a controversial theory known as the amyloid hypothesis, which states that Alzheimer’s disease is caused primarily by the buildup of plaques in the brain.

Advertisement

“It’s been shown that amyloid beta causes Alzheimer’s disease as much as HIV causes AIDS. I think it’s the same level of evidence,” he claims.

Many researchers disagree that amyloid beta is now proven to be the “primary cause” of Alzheimer’s disease, saying that it is a complex disease with many contributing factors.

“Amyloid beta probably contributes about 30 percent to overall disease, but there are many other disease proteins and other conditions that can increase the rate of decline,” said Dr. Keith Fossell, a UCLA professor of neuroscience. Angeles.

It was Lanvelt’s discovery in the early 1990s of a mutation in the gene responsible for beta-amyloid that helped establish a link between sticky plaques and Alzheimer’s disease. Nearly a decade later while working as a researcher at Karolinska Institutet — a Swedish medical body — he discovered another genetic mutation linked to beta-amyloid clusters called profibrils, the rod-like structures that are a key target for lecanemab.

Dubbed the ‘Arctic mutation’, it led to the discovery of the mAb158 monoclonal antibody, which became lecanemab.

Advertisement

said Lanfelt, who owns 33.5 percent of BioArctic stock but controls 49.3 percent of the biotech’s voting rights. He sold a small portion of his stake in October.

If likanimab turns out to be a commercial success, Lanfelt said, BioArctic will use the proceeds to develop drugs targeting Parkinson’s disease and other disorders of the central nervous system. Despite his age, he said he wants to continue working at BioArctic as long as he can contribute to research.

“You can’t change your lifestyle at this age,” Lanfelt said, adding that he would indulge himself in buying an electric car.


Source link

Advertisement
Continue Reading

Finance

Elon Musk is attacking former Twitter leaders by trying to refocus attention on the Republican Party’s favorite target: Hunter Biden and his laptop.

Avatar

Published

on


Twitter CEO Elon Musk renewed his attack on his company’s past leadership on Friday by touting what he described as evidence of the “suppression of the Hunter Biden story.”

In fact, the alleged evidence was the work of a freelance journalist who had access to internal Twitter emails showing the controversy within the company over restricting New York Post Article in 2020 about the contents of a laptop computer belonging to then-presidential candidate Joe Biden’s son. Twitter initially restricted users’ access to this article, fueling allegations by Republicans that the company was trying to suppress harmful information about Biden ahead of the election.

Musk, who has tried to win over Republicans since taking over Twitter in October, seized on the topic as explosive new information about the company’s preference for Democrats over Republicans. In fact, Highlighted emails are only back and forth between Twitter employees and the Biden campaign team, which asked Twitter to remove several of the tweets.

The journalist who published the emails on Friday, Matt Tibi, did not disclose the contents of the tweets in question. but some Twitter users following the scene found it The deleted tweets were pornographic images of Biden.

Advertisement



one email Shows that at least one democrat was concerned about twitter censorship for New York Post a story. Democratic Rep. Ro Khanna wrote to Vijaya Gaddy, Twitter’s former head of legal, policy and trust, to say the ban on the article was “generating massive backlash on the hills” and offering chat.

Jack Dorsey, CEO of Twitter at the time, eventually disavow it Twitter ban for New York Post Article. At first, he had no idea the article had been banned, according to Taibi, who painted the decision as one that Dorsey’s team made out of control.

“There are multiple instances in Dorsey’s files in which she enters into question the suspension and other moderation measures, for accounts across the political spectrum,” Wroteapparently clearing Dorsey, Musk’s friend, of political bias.



Source link

Advertisement



Continue Reading
Advertisement

Trending